secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2022-12-06T23:59:59+00:00
Accession:  0001558370-22-018383
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas reports positive Phase 1/2 RUBY trial data for EDIT-301 in sickle cell disease
--------------------------------------------------------------------------------

- First two patients engrafted successfully; no vaso-occlusive events after treatment with EDIT-301.
- Patient 1 at 5 months post-treatment: total hemoglobin 16.4 g/dL, fetal hemoglobin 45.4%, HbF pancellular >95%.
- EDIT-301 well-tolerated; safety profile consistent with myeloablative conditioning and autologous transplant.
- First clinical use of proprietary AsCas12a nuclease to edit human cells; further data expected mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000155837022018383/0001558370-22-018383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000155837022018383/edit-20221206x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-018383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer